Structural and electrostatic analysis of HLA B-cell epitopes: Inference on immunogenicity and prediction of humoral alloresponses

Current Opinion in Organ Transplantation

Volumn 19, Issue 4, 2014, Pages 420-427

  Mallon, Dermot H ^a   Bradley, J A ^a   Taylor, Craig J ^b   Kosmoliaptsis, Vasilis ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Antigenicity; Computational structure prediction; Electrostatics; Human leukocyte antigen; Immunogenicity

Indexed keywords

ALLOANTIGEN; EPITOPE; HLA ANTIGEN;

ALLOIMMUNITY; ANTIGEN STRUCTURE; ANTIGENICITY; B LYMPHOCYTE; COMPLEMENTARITY DETERMINING REGION; HLA SYSTEM; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOGLOBULIN STRUCTURE; REVIEW; STATIC ELECTRICITY; ANTIBODY PRODUCTION; CHEMISTRY; GENETICS; IMMUNOLOGY; INNATE IMMUNITY;

ANTIBODY FORMATION; EPITOPES, B-LYMPHOCYTE; HLA ANTIGENS; HUMANS; IMMUNITY, INNATE; ISOANTIGENS; STATIC ELECTRICITY;

EID: 84904202359     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000108     Document Type: Review

References (68)

1. Mehra NK, Siddiqui J, Baranwal A, et al. Clinical relevance of antibody development in renal transplantation. Ann N Y Acad Sci 2013; 1283:30-42.
2. Cosio FG, Gloor JM, Sethi S, et al. Transplant glomerulopathy. Am J Transplant 2008; 8:492-496.
3. O'Leary JG, Kaneku H, Jennings LW, et al. Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation. Liver Transpl 2013; 19:973-980.
4. Kaneku H, O'Leary JG, Banuelos N, et al. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant 2013; 13:1541-1548.
5. Opelz G, Dohler B. Effect of human leukocyte antigen compatibility on kidney graft survival: comparative analysis of two decades. Transplantation 2007; 84:137-143.
6. Morris PJ, Johnson RJ, Fuggle SV, et al. Analysis of factors that affect outcome of primary cadaveric renal transplantation in the UK. HLA Task Force of the Kidney Advisory Group of the United Kingdom Transplant Support Service Authority (UKTSSA). Lancet 1999; 354:1147-1152.
7. Doxiadis II, Smits JM, Schreuder GM, et al. Association between specific HLA combinations and probability of kidney allograft loss: the taboo concept. Lancet 1996; 348:850-853.
8. Duquesnoy RJ. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. I. Description of the algorithm. Hum Immunol 2002; 63:339-352.
9. Duquesnoy RJ. A structurally based approach to determine HLA compatibility at the humoral immune level. Hum Immunol 2006; 67:847-862.
10. Dankers MK, Witvliet MD, Roelen DL, et al. The number of amino acid triplet differences between patient and donor is predictive for the antibody reactivity against mismatched human leukocyte antigens. Transplantation 2004; 77:1236-1239.
11. Kosmoliaptsis V, Bradley JA, Sharples LD, et al. Predicting the immunogenicity of human leukocyte antigen class I alloantigens using structural epitope analysis determined by HLAMatchmaker. Transplantation 2008; 85:1817-1825.
12. Goodman RS, Taylor CJ, O'Rourke CM, et al. Utility of HLAMatchmaker and single-antigen HLA-antibody detection beads for identification of acceptable mismatches in highly sensitized patients awaiting kidney transplantation. Transplantation 2006; 81:1331-1336.
13. Claas FH, Rahmel A, Doxiadis II. Enhanced kidney allocation to highly sensitized patients by the acceptable mismatch program. Transplantation 2009; 88:447-452.
14. Claas FH, Witvliet MD, Duquesnoy RJ, et al. The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: short waiting time and excellent graft outcome. Transplantation 2004; 78:190-193.
15. Duquesnoy RJ, Takemoto S, de Lange P, et al. HLAmatchmaker: a molecularly based algorithm for histocompatibility determination. III. Effect of matching at the HLA-A,B amino acid triplet level on kidney transplant survival. Transplantation 2003; 75:884-889.
16. Duquesnoy RJ, Marrari M. HLAMatchmaker-based definition of structural human leukocyte antigen epitopes detected by alloantibodies. Curr Opin Organ Transplant 2009; 14:403-409.
17. Duquesnoy RJ. Antibody-reactive epitope determination with HLAMatchmaker and its clinical applications. Tissue Antigens 2011; 77:525-534.
18. Wiebe C, Pochinco D, Blydt-Hansen TD, et al. Class II HLA epitope matching: a strategy to minimize de novo donor-specific antibody development and improve outcomes. Am J Transplant 2013; 13:3114-3122.
19. Duquesnoy RJ, Marrari M, da M Sausa LC, et al. 16th IHIW: a website for antibody-defined HLA epitope registry. Int J Immunogenet 2013; 40:54-59.
20. Kosmoliaptsis V, Chaudhry AN, Sharples LD, et al. Predicting HLA class I alloantigen immunogenicity from the number and physiochemical properties of amino acid polymorphisms. Transplantation 2009; 88:791-798.
21. Kosmoliaptsis V, Sharples LD, Chaudhry AN, et al. Predicting HLA class II alloantigen immunogenicity from the number and physiochemical properties of amino acid polymorphisms. Transplantation 2011; 91:183-190.
22. Kosmoliaptsis V, Sharples LD, Chaudhry AN, et al. HLA class I amino acid sequence-based matching after interlocus subtraction and long-term outcome after deceased donor kidney transplantation. Hum Immunol 2010; 71:851-856.
23. Dunbar J, Krawczyk K, Leem J, et al. SAbDab: the structural antibody database. Nucleic Acids Res 2014; 42:D1140-D1146.
24. Hülsmeyer M, Chames P, Hillig RC, et al. A major histocompatibility complexpeptide- restricted antibody and T cell receptor molecules recognize their target by distinct binding modes: crystal structure of human leukocyte antigen (HLA)- A1-MAGE-A1 in complex with FAB-HYB3. J Biol Chem 2005; 280:2972-2980.
25. Hu Z, Ma B, Wolfson H, et al. Conservation of polar residues as hot spots at protein interfaces. Proteins 2000; 39:331-342.
26. Kastritis PL, Bonvin AMJJ. On the binding affinity of macromolecular interactions: daring to ask why proteins interact. J R Soc Interface 2013; 10:20120835.
27. Moreira IS, Fernandes PA, Ramos MJ. Hot spots: a review of the proteinprotein interface determinant amino-acid residues. Proteins 2007; 68:803-812.
28. Calis JJA, Maybeno M, Greenbaum JA, et al. Properties of MHC class I presented peptides that enhance immunogenicity. PLoS Comput Biol 2013; 9:e1003266.
29. Brusic V, Bajic VB, Petrovsky N. Computational methods for prediction of Tcell epitopes: a framework for modelling, testing, and applications. Methods 2004; 34:436-443.
30. Kim Y, Sette A, Peters B. Applications for T-cell epitope queries and tools in the Immune Epitope Database and Analysis Resource. J Immunol Methods 2011; 374:62-69.
31. Yao B, Zheng D, Liang S, et al. Conformational B-cell epitope prediction on antigen protein structures: a review of current algorithms and comparison with common binding site prediction methods. PLoS One 2013; 8:e62249.
32. Eswar N, Webb B, Marti-Renom MA, et al. Comparative protein structure modeling using Modeller. Curr Protoc Bioinformatics 2006; 1-30; Chapter 5:Unit 5.6.
33. Kryshtafovych A, Fidelis K, Moult J. CASP10 results compared to those of previous CASP experiments. Proteins 2014; 82 (Suppl 2):164-174.
34. Sircar A, Kim ET, Gray JJ. RosettaAntibody: antibody variable region homology modeling server. Nucleic Acids Res 2009; 37:W474-W479.
35. Sircar A, Gray JJ. SnugDock: paratope structural optimization during antibody- antigen docking compensates for errors in antibody homology models. PLoS Comput Biol 2010; 6:e1000644.
36. Pedotti M, Simonelli L, Livoti E, et al. Computational docking of antibodyantigen complexes, opportunities and pitfalls illustrated by influenza hemagglutinin. Int J Mol Sci 2011; 12:226-251.
37. Persson BA, Jonsson B, Lund M. Enhanced protein steering: cooperative electrostatic and van der Waals forces in antigen-antibody complexes. J Phys Chem B 2009; 113:10459-10464.
38. Chandler D. Interfaces and the driving force of hydrophobic assembly. Nature 2005; 437:640-647.
39. Zhang Z, Witham S, Alexov E. On the role of electrostatics in protein-protein interactions. Phys Biol 2011; 8:035001.
40. Honig B, Nicholls A. Classical electrostatics in biology and chemistry. Science 1995; 268:1144-1149.
41. Sinha N, Smith-Gill SJ. Electrostatics in protein binding and function. Curr Protein Pept Sci 2002; 3:601-614.
42. Slagle SP, Kozack RE, Subramaniam S. Role of electrostatics in antibodyantigen association: anti-hen egg lysozyme/lysozyme complex (HyHEL-5/ HEL). J Biomol Struct Dyn 1994; 12:439-456.
43. Mohan S, Kourentzi K, Schick KA, et al. Association energetics of crossreactive and specific antibodies. Biochemistry 2009; 48:1390-1398.
44. Sinha N, Mohan S, Lipschultz CA, et al. Differences in electrostatic properties at antibody-antigen binding sites: implications for specificity and crossreactivity. Biophys J 2002; 83:2946-2968.
45. Chong LT, Duan Y, Wang L, et al. Molecular dynamics and free-energy calculations applied to affinity maturation in antibody 48G7. Proc Natl Acad Sci USA 1999; 96:14330-14335.
46. Botti SA, Felder CE, Sussman JL, et al. Electrotactins: a class of adhesion proteins with conserved electrostatic and structural motifs. Protein Eng 1998; 11:415-420.
47. Grochowski P, Trylska J. Continuum molecular electrostatics, salt effects, and counterion binding: a review of the Poisson-Boltzmann theory and its modifications. Biopolymers 2008; 89:93-113.
48. Dolinsky TJ, Nielsen JE, McCammon JA, et al. PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. Nucleic Acids Res 2004; 32:W665-W667.
49. Dong F, Olsen B, Baker NA. Computational methods for biomolecular electrostatics. Methods Cell Biol 2008; 84:843-870.
50. Warshel A, Sharma PK, Kato M, et al. Modeling electrostatic effects in proteins. Biochim Biophys Acta 2006; 1764:1647-1676.
51. Schutz CN, Warshel A. What are the dielectric ''constants'' of proteins and how to validate electrostatic models? Proteins 2001; 44:400-417.
52. Connolly ML. Solvent-accessible surfaces of proteins and nucleic acids. Science 1983; 221:709-713.
53. Decherchi S, Colmenares J, Catalano CE. Between algorithm and model: different molecular surface definitions for the Poisson-Boltzmann based electrostatic characterization of biomolecules in solution. Commun Comput Phys 2013; 13:61-89.
54. Baker NA. Improving implicit solvent simulations: a Poisson-centric view. Curr Opin Struct Biol 2005; 15:137-143.
55. Li C, Li L, Petukh M, Alexov E. Progress in developing Poisson-Boltzmann equation solvers. Mol based Math Biol 2013; 1:42-62.
56. Tan C, Yang L, Luo R. How well does Poisson-Boltzmann implicit solvent agree with explicit solvent? A quantitative analysis. J Phys Chem B 2006; 110:18680-18687.
57. Zhou H-X, Dong F. Electrostatic contributions to the stability of a thermophilic cold shock protein. Biophys J 2003; 84:2216-2222.
58. Wang T, Wade RC. Implicit solvent models for flexible protein-protein docking by molecular dynamics simulation. Proteins 2003; 50:158-169.
59. Suzuki H, Nishizawa T, Tani K, et al. Crystal structure of a claudin provides insight into the architecture of tight junctions. Science 2014; 344:304-307.
60. Pinto TM, Wedemann RS, Cortez CM. Modeling the electric potential across neuronal membranes: the effect of fixed charges on spinal ganglion neurons and neuroblastoma cells. PLoS One 2014; 9:e96194.
61. Kosmoliaptsis V, Dafforn TR, Chaudhry AN. High-resolution, three-dimensional modeling of human leukocyte antigen class I structure and surface electrostatic potential reveals the molecular basis for alloantibody binding epitopes. Hum Immunol 2011; 72:1049-1059.
62. Taylor CJ, Kosmoliaptsis V, Summers DM, et al. Back to the future: application of contemporary technology to long-standing questions about the clinical relevance of human leukocyte antigen-specific alloantibodies in renal transplantation. Hum Immunol 2009; 70:563-568.
63. Gebel HM, Liwski RS, Bray RA. Technical aspects of HLA antibody testing. Curr Opin Organ Transplant 2013; 18:455-462.
64. Duquesnoy RJ, Marrari M, Jelenik L, et al. Structural aspects of HLA class I epitopes reacting with human monoclonal antibodies in Ig-binding, C1qbinding and lymphocytotoxicity assays. Hum Immunol 2013; 74:1271-1279.
65. Baker NA, Sept D, Joseph S, et al. Electrostatics of nanosystems: application to microtubules and the ribosome. Proc Natl Acad Sci USA 2001; 98:10037-10041.
66. Hodgkin E, Richards W. Molecular similarity based on electrostatic potential and electric field. Int J Quantum Chem 1987; 32:105-110.
67. Blomberg N, Gabdoulline RR, Nilges M, et al. Classification of protein sequences by homology modeling and quantitative analysis of electrostatic similarity. Proteins 1999; 37:379-387.
68. Wade RC, Gabdoulline RR, De Rienzo F. Protein interaction property similarity analysis. Int J Quantum Chem 2001; 83:122-127.